MetaCap

Cytosorbents (CTSO) vs Picard Medical (PMI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cytosorbents (CTSO) has outperformed Picard Medical (PMI) over the past year, losing 70.6% versus a loss of 94.0%. Picard Medical is the larger company by market cap ($18.1 million vs $13.1 million), about 1.4 times the size. Cytosorbents converts more of its revenue into profit, with a net margin of -22.1% versus -546.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTSO-70.58%PMI-94.02%
+71%-17%-105%
Nov 21, 20251 yearNov 20, 2026
CTSO-77.94%PMI-97.04%
+123%+7%-109%
Aug 25, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTSO versus PMI key metrics
MetricCTSOPMI
Share price$4.16$6.79
Market cap$13.12M$18.07M
1-day change-18.91%+7.78%
YTD return-67.45%-92.24%
1-year return-70.58%-94.02%
5-year return-95.62%—
P/E ratio (TTM)—3.04
EPS (TTM)$-5.62$2.23
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$37.06M$4.94M
Revenue growth (YoY)+4.12%+12.50%
Net income (latest FY)$-8.20M$-27.00M
Gross margin71.48%-4.13%
Operating margin-39.79%-268.36%
Net margin-22.12%-546.60%
52-week high$17.00$208.00
52-week low$2.84$2.65
Distance from 52-week high-75.53%-96.74%
Analyst consensusnone—
Avg. price target upside+1041.83%—
Average volume37.34K1.45M
Shares outstanding3.15M2.66M
Employees12975
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CTSO has outperformed PMI by 23.4 percentage points over the past year.
  • Cytosorbents is more profitable, keeping -22.1 cents of every revenue dollar as net income versus -546.6 cents for Picard Medical.
  • Picard Medical grew revenue faster in its latest fiscal year (+12.50% vs +4.12%).

About Cytosorbents

CTSO stock →

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.

Health Care · Medical/Dental Instruments · 129 employees

About Picard Medical

PMI stock →

Picard Medical, Inc., together with its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products. The company offers SynCardia TAH, an artificial heart for patients that is designed to function as a failed human heart in patients suffering from advanced heart failure.

Health Care · Medical/Dental Instruments · 75 employees

CTSO vs PMI FAQ

Which is bigger, Cytosorbents or Picard Medical?

Picard Medical (PMI) is larger, with a market capitalization of $18.07M compared with $13.12M for Cytosorbents (CTSO).

Which stock has performed better over the past year, CTSO or PMI?

CTSO returned -70.58% over the past 12 months, compared with -94.02% for PMI (price return, excluding dividends). Past performance does not predict future results.

Are Cytosorbents and Picard Medical in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons